NurExone Biologic Inc.

TSXV:NRX Stock Report

Market Cap: CA$58.8m

NurExone Biologic Management

Management criteria checks 1/4

NurExone Biologic's CEO is Lior Shaltiel, appointed in Jun 2022, has a tenure of 3.42 years. total yearly compensation is $280.33K, comprised of 77.3% salary and 22.7% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth CA$301.75K. The average tenure of the management team and the board of directors is 1.4 years and 3.4 years respectively.

Key information

Lior Shaltiel

Chief executive officer

US$280.3k

Total compensation

CEO salary percentage77.34%
CEO tenure3.4yrs
CEO ownership0.5%
Management average tenure1.4yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

We're Keeping An Eye On NurExone Biologic's (CVE:NRX) Cash Burn Rate

Jun 12
We're Keeping An Eye On NurExone Biologic's (CVE:NRX) Cash Burn Rate

CEO Compensation Analysis

How has Lior Shaltiel's remuneration changed compared to NurExone Biologic's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$6m

Mar 31 2025n/an/a

-US$6m

Dec 31 2024US$280kUS$217k

-US$5m

Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$214kUS$214k

-US$4m

Sep 30 2023n/an/a

-US$4m

Jun 30 2023n/an/a

-US$4m

Mar 31 2023n/an/a

-US$7m

Dec 31 2022US$296kUS$246k

-US$8m

Compensation vs Market: Lior's total compensation ($USD280.33K) is above average for companies of similar size in the Canadian market ($USD162.92K).

Compensation vs Earnings: Lior's compensation has increased whilst the company is unprofitable.

CEO

Lior Shaltiel

3.4yrs
Tenure
US$280,333
Compensation

Dr. Lior Shaltiel, Ph D., is the Chief Executive Officer and Director of NurExone Biologic Inc., since June 15, 2022. Dr. Shaltiel is an entrepreneur and an awarded scientist with extensive multidisciplina...

Leadership Team

NamePositionTenureCompensationOwnership
Yoram Drucker
Co-Founder3.4yrsUS$128.21k4.42%
CA$ 2.6m
Lior Shaltiel
CEO & Director3.4yrsUS$280.33k0.51%
CA$ 301.8k
Eran Ovadya
CFO, Financial Director & Secretary3.4yrsUS$281.36k0.51%
CA$ 301.8k
Gabriel Eldor
Co-Founder & Business Development Managerno datano datano data
Shulamit Levenberg
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Daniel Offen
Co-Founderno datano datano data
Tali Kizhner
Director of Research & Developmentless than a yearno datano data
Jacob Licht
CEO of Exo-Top Inc. & VP of Corporate Development at NurExoneno datano datano data
Nahshon Knoller
Head of the neurosurgery department at Shiba & Member of Scientific Advisory Board1.8yrsno datano data
Ina Sarel
Head of CMC1.4yrsno datano data
Nirit Drori-Carmi
Head of Bioprocess Development1.4yrsno datano data
Limor Chen
Head of Scientific Collaboration & External Partnerships1.1yrsno datano data
1.4yrs
Average Tenure

Experienced Management: NRX's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Yoram Drucker
Co-Founder3.4yrsUS$128.21k4.42%
CA$ 2.6m
Lior Shaltiel
CEO & Director3.4yrsUS$280.33k0.51%
CA$ 301.8k
Shulamit Levenberg
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Nahshon Knoller
Head of the neurosurgery department at Shiba & Member of Scientific Advisory Boardno datano datano data
Teodoro Dagi
Member of Scientific Advisory Board2.1yrsno datano data
James Richardson
Independent Director14.4yrsUS$9.75k0.21%
CA$ 122.0k
Michael Belkin
Member of Scientific Advisory Boardno datano datano data
Oded Orgil
Director3.4yrsUS$9.93kno data
Gabriel Zeilig
Member of Scientific Advisory Boardno datano datano data
Gadi Riesenfeld
Independent Director2.3yrsUS$9.72kno data
3.4yrs
Average Tenure
69yo
Average Age

Experienced Board: NRX's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/07 17:58
End of Day Share Price 2025/11/07 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NurExone Biologic Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bradley SorensenZacks Small-Cap Research